Physician profile
John P Bertsch
NPI 1326004334
$9,191.28
in general payments reported to CMS, 2019-2025
50 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $223 · 2022: $707 · 2023: $1,531 · 2024: $2,423 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,614.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,123.46 | 2019-2025 | |
| Novo Nordisk INC | $1,059.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $754.77 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Amgen INC. | $686.32 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $686.10 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.66 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| E.R. Squibb & Sons, L.L.C. | $489.51 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $436.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $426.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $350.79 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $292.28 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $257.86 | 2019-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $171.93 | 2023-2025 | Gvoke Hypopen |
| Radius Health, INC. | $160.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $149.72 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bertsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.